Stage III XXXX . A detailed analysis.

@entity1 @entity0 @entity66 @entity2617 @entity4 @entity1066 @entity5
A ten-year study of @entity0 has been reviewed in detail. The single most dominant variable was axillary nodal involvement. Four hundred and thirty @entity1 had nodal metastases, 58 @entity1 did not. Four hundred and thirty @entity1 with axillary nodal involvement had fiveand ten-year recurrence rates of 68 and 77%, while the survival rates were 41 and 21%, respectively. Life span was influenced by extent of @entity66 , being best for those with micrometastases only, and worse for those with four or more positive nodes. Skin @entity4 , @entity2617 , or @entity1066 in the positive node group were grave signs. Muscle invasion or node matting, however, did not appear to influence length of life. Postoperative prophylactic therapy did not appear to affect survival rates. Radiation therapy alone did not influence either local recurrence or survival rates. Not enough time has elapsed to evaluate the results of postoperative chemotherapy. @entity1 who underwent oophorectomy and radiation therapy appeared to do better, but the number of @entity1 was small. Of the 58 @entity1 without nodal invasion, 82% were alive at five years and 75% were alive at 10 years. Grave signs did not influence the survival rate in this group. While the majority of @entity1 with @entity5 had unfavorable variables, there were some @entity1 who demonstrated a low recurrence rate and a long survival time. Aggressive treatment should be designed to save those @entity1 who can be helped and to improve those @entity1 whose life expectancy is limited. There is no place for timid initial treatment whether by operation or by irradiation. It must be given with intent to cure even though palliation is most often attained.
